A new comprehensive review published in Journal of Stroke, written by STROKE BRNO members and our foreign collaborators brings updated information about currently available thrombolytics, strategies for…
Our Publications
Diseases with the highest burden for society such as stroke, myocardial infarction, pulmonary embolism, and others are due to blood clots. Preclinical and clinical techniques to study…
Myocardial infarction and ischemic stroke are the most frequent causes of death or disability worldwide. Due to their ability to dissolve blood clots, the thrombolytics are frequently…
Introduction of microfluidic mixing technique opens a new door for preparation of the liposomes and lipid-based nanoparticles by on-chip technologies that are applicable in a laboratory and…
Gadolinium (Gd)–based contrast agents are extensively used for magnetic resonance imaging (MRI). Liposomes are potential nanocarrier–based biocompatible platforms for development of new generations of MRI diagnostics. Liposomes…
Polysaccharides are important group of compounds used in pharmaceutical industry. Their utilization in formulation of potential nanomedicine drug carriers includes formulation of nanoparticles from polysaccharides itself, encapsulation…
Development of tools for direct thrombus imaging represents a key step for diagnosis and treatment of stroke. Nanoliposomal carriers of contrast agents and thrombolytics can be functionalized…
The development of new drugs and curative treatments without animal models is currently not possible. Due to the unique complexity of stroke, the number of models studying…
Clinical studies consistently report structural impairments (i.e.: ventricular enlargement, decreased volume of anterior cingulate cortex or hippocampus) and functional abnormalities including changes in regional cerebral blood flow…
Olanzapine is a frequently used atypical antipsychotic drug known to exert structural brain alterations in animals. This study investigated whether chronic olanzapine exposure alters regional blood brain…